<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117787">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02059369</url>
  </required_header>
  <id_info>
    <org_study_id>GER-EP-13</org_study_id>
    <nct_id>NCT02059369</nct_id>
  </id_info>
  <brief_title>Ablation of Complex Fractionated Electrograms With or Without Additional Linear Lesions for Persistent Atrial Fibrillation</brief_title>
  <acronym>ADLINE</acronym>
  <official_title>Ablation of Complex Fractionated Electrograms With or Without Additional Linear Lesions for Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While there is a consensus to perform pulmonary vein isolation (PVI) as a cornerstone for
      paroxysmal and persistent atrial fibrillation (AF), different additional ablation approaches
      are used for substrate modification: linear lesions, ablation of complex fractionated atrial
      electrograms (CFAE) or a combination of both. The aim of this study is to determine whether
      there is a difference in terms of freedom from arrhythmia recurrence between PVI with CFAE
      ablation in combination or not with linear lesions in patients with persistent AF.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Freedom from atrial arrhythmia</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Documented freedom from atrial arrhythmia (AF or AT) recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural and safety data</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Duration of procedure, ablation time, fluoroscopy time and complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and result of reablation procedure</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of redo procedures, results and type of recurrent arrhythmia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Recurrence</condition>
  <arm_group>
    <arm_group_label>CFAE ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Complex fractionated atrial electrograms (CFAE) Ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CFAE + Lines</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CFAE Ablation followed by linear lesions (anterior and Roof line)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVI+CFAE+DCC</intervention_name>
    <description>pulmonary vein Isolation (PVI), CFAE for substrate modification and direct current cardioversion (DCC) if AF persists</description>
    <arm_group_label>CFAE ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVI, CFAE, anterior and roof line, DCC</intervention_name>
    <description>PVI, CFAE ablation. If AF persists linear lesions (anterior and roof line), cardioversion if AF persists</description>
    <arm_group_label>CFAE + Lines</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with symptomatic persistent AF

          -  After PVI +CFAE ablation, no termination into sinusrhythm or atrial tachycardia

        Exclusion Criteria:

          -  Left atrial thrombus
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sonia Ammar, MD</last_name>
    <phone>+49891218</phone>
    <phone_ext>2020</phone_ext>
    <email>ammar@dhm.mhn.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Deutsches Herzzentrum MÃ¼nchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Ammar, MD</last_name>
      <phone>+491218</phone>
      <phone_ext>2020</phone_ext>
      <email>ammar@dhm.mhn</email>
    </contact>
    <investigator>
      <last_name>Sonia Ammar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>February 7, 2014</lastchanged_date>
  <firstreceived_date>May 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Recurrence</keyword>
  <keyword>CFAE</keyword>
  <keyword>linear ablation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
